Our Team
Our founder
Dr Jeff Moore
Dr Moore’s career has focused on the regulation of cell production in the body’s two most regenerative tissues: the bone marrow and the single layer of the intestinal mucosa. He holds a PhD in genetics from George Washington University and has spent over 40 years researching cell production and developing novel treatments. Dr Moore founded Phylogix Inc and led the discovery and development of a protein (FRIL) through to late preclinical development.
Dr Jeff Moore
Founder and CEO
Dr Moore’s career has focused on the regulation of cell production in the body’s two most regenerative tissues: the bone marrow and the single layer of the intestinal mucosa.
His PhD research conducted at the US National Institutes of Health (NIH) changed the understanding of the genetic basis of paroxysmal nocturnal haemaglobinuria (PNH).[i]
Dr Moore’s search for regulators of cell production started as a post-doctoral fellow of Dr Don Metcalf at the Walter and Elisa Hall Institute (WEHI) in Melbourne, founder of the field of blood cell production.
Based on some early research, Dr Moore set out at WEHI to identify the body’s regulators that protect stem cells (engine for cell production) from the toxicity of chemotherapy. The search continued at DNAX Research Institute in Palo Alto and at ImClone Systems Inc in New York City.
At ImClone, Dr Moore discovered a protein (FRIL) that maintained blood stem cells in culture for extended periods and were capable of repopulating long-term blood cell production. He founded Phylogix Inc in the Boston area and advanced FRIL to late preclinical development with $15m venture capital funding from Atlas Venture, Biotechnology Value Fund, Canaan Partners, Prospect Venture Partners and Radius Ventures.
Dr Moore then moved to the body’s other most regenerative tissue, the mucosal layer of the gut. He joined Prof Chris Potten, founder of the epithelial stem cell field, at Epistem Ltd in Manchester, UK. Dr Moore created and led a regenerative medicine collaboration with Novartis Institutes of BioMedical Research (NIBR), where his team developed and validated in vitro models that delivered the core technology at Curileum.
Dr Moore graduated from Colorado College with a BA in chemistry and from George Washington University with a PhD in genetics.
[i] https://pubmed.ncbi.nlm.nih.gov/2413153/
The team
Our expert team
Curileum is guided by an experienced team of scientific and clinical advisors.
Consultants
-
Dr Jeff Moore
Read bio
Dr Jeff Moore
Founder and CEO
Dr Moore’s career has focused on the regulation of cell production in the body’s two most regenerative tissues: the bone marrow and the single layer of the intestinal mucosa.
His PhD research conducted at the US National Institutes of Health (NIH) changed the understanding of the genetic basis of paroxysmal nocturnal haemaglobinuria (PNH).[i]
Dr Moore’s search for regulators of cell production started as a post-doctoral fellow of Dr Don Metcalf at the Walter and Elisa Hall Institute (WEHI) in Melbourne, founder of the field of blood cell production.
Based on some early research, Dr Moore set out at WEHI to identify the body’s regulators that protect stem cells (engine for cell production) from the toxicity of chemotherapy. The search continued at DNAX Research Institute in Palo Alto and at ImClone Systems Inc in New York City.
At ImClone, Dr Moore discovered a protein (FRIL) that maintained blood stem cells in culture for extended periods and were capable of repopulating long-term blood cell production. He founded Phylogix Inc in the Boston area and advanced FRIL to late preclinical development with $15m venture capital funding from Atlas Venture, Biotechnology Value Fund, Canaan Partners, Prospect Venture Partners and Radius Ventures.
Dr Moore then moved to the body’s other most regenerative tissue, the mucosal layer of the gut. He joined Prof Chris Potten, founder of the epithelial stem cell field, at Epistem Ltd in Manchester, UK. Dr Moore created and led a regenerative medicine collaboration with Novartis Institutes of BioMedical Research (NIBR), where his team developed and validated in vitro models that delivered the core technology at Curileum.
Dr Moore graduated from Colorado College with a BA in chemistry and from George Washington University with a PhD in genetics.
[i] https://pubmed.ncbi.nlm.nih.gov/2413153/